APOA2 and pancreatic intraductal papillary-mucinous neoplasm: The findings of a retrospective study indicate that low serum levels of APOA2-ATQ/AT can be a potential biomarker for identifying intraductal papillary mucinous neoplasm (IPMN) patients at high risk of developing PDAC.